Should I Buy CCOI? CCOI 2026 Analysis - Intellectia AI™

Loading...

Should You Buy Cogent Communications Holdings Inc (CCOI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

24.290

1 Day change

7.72%

52 Week Range

84.060

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: fundamentals are weakening (revenue down, losses widening) and sentiment is negative ahead of earnings.
Price is sitting near the pivot (~~24.19) with no strong technical breakout signal; upside to resistance (~~25.20) looks limited versus downside risk to support (~23.17 / ~22.54).
Options are pricing elevated uncertainty (very high IV/percentile), consistent with a potentially volatile earnings setup rather than a clean entry.
News flow (fraud investigation headline + an institutional exit) is an added near-term overhang.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is positive (0.111) but contracting, implying bullish momentum is fading rather than accelerating.
RSI: RSI(6) ~56 (neutral-to-slightly bullish), not indicating an oversold “bounce” setup.
Moving averages: Converging MAs suggest consolidation/chop instead of a decisive uptrend.
Key levels: Pivot 24.185 is basically current price (~24.25–24.26 pre-market). Near-term resistance R1 ~25.203 then R2 ~25.832. Supports S1 ~23.167 then S2 ~22.538.
Pattern-based odds (provided): biased upward over 1W/1M, but this is not confirmed by strong momentum signals today and clashes with weak fundamentals/news.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call at 0.19 suggests call-heavy positioning (more bullish structure), but put/call volume ~1.01 is essentially neutral on the day.
Volatility: 30D IV ~92.9 with IV percentile ~96 (very elevated). Market is pricing large moves/uncertainty (not a calm accumulation profile).
Activity: Volume is above typical (today vs 30D avg ~108%), consistent with heightened event positioning.
Takeaway: Options imply “high uncertainty / event risk” rather than a clean bullish consensus.

Technical Summary

dotted line Image

Sell

2

Buy

9

Positive Catalysts

and reclaiming ~25.20 could trigger a short-term momentum push.

Neutral/Negative Catalysts

increases gap-risk; elevated IV confirms the market expects big moves.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $241.9M, -5.93% YoY (top-line contraction).
Profitability: Net income -$41.5M (loss widened ~-34.17% YoY); EPS -0.87 (down ~-34.59% YoY).
Margins: Gross margin 20.6% (up sharply YoY per snapshot), but improvement in gross margin has not translated into bottom-line profitability yet.
Growth takeaway: The quarter shows weakening demand/uptake and continued losses—doesn’t support an “impatient buy-now” posture.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Rating/target trend (recent months): Broadly negative—multiple firms cut price targets sharply and several downgraded to Neutral/Equal Weight, reflecting reduced confidence after softer results and capital return changes.
Notable latest view: BofA Underperform with target cut again to $21 (from $25) on 2026-01-21.
Cluster of reduced targets: JPMorgan to $23, RBC to $23, Citi to $25, UBS downgraded to Neutral with $27, Wells Fargo downgraded to Equal Weight with $27; KeyBanc stayed Overweight but cut to $30.
Wall Street pros: If wavelength/waves product inflects and leverage improves, upside re-rating is possible; a few firms still maintain more constructive stances (e.g., Overweight/Outperform maintained by some).
Wall Street cons (dominant): Sluggish wavelength ramp, competitive pressure, weaker financial/customer metrics, and leverage/capital allocation constraints (dividend/buyback changes) keep the risk profile elevated.

People Also Watch